ES3063485T3 - Compositions and methods of using itaconic acid derivatives - Google Patents

Compositions and methods of using itaconic acid derivatives

Info

Publication number
ES3063485T3
ES3063485T3 ES19826034T ES19826034T ES3063485T3 ES 3063485 T3 ES3063485 T3 ES 3063485T3 ES 19826034 T ES19826034 T ES 19826034T ES 19826034 T ES19826034 T ES 19826034T ES 3063485 T3 ES3063485 T3 ES 3063485T3
Authority
ES
Spain
Prior art keywords
disease
alkyl
compounds
pharmaceutical composition
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19826034T
Other languages
English (en)
Spanish (es)
Inventor
Adonia Papathanassiu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ergon Pharmaceuticals LLC
Original Assignee
Ergon Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ergon Pharmaceuticals LLC filed Critical Ergon Pharmaceuticals LLC
Application granted granted Critical
Publication of ES3063485T3 publication Critical patent/ES3063485T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/44—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES19826034T 2018-06-29 2019-07-01 Compositions and methods of using itaconic acid derivatives Active ES3063485T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862763735P 2018-06-29 2018-06-29
PCT/US2019/040121 WO2020006557A1 (en) 2018-06-29 2019-07-01 Compositions and methods of using itaconic acid derivatives

Publications (1)

Publication Number Publication Date
ES3063485T3 true ES3063485T3 (en) 2026-04-16

Family

ID=68985877

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19826034T Active ES3063485T3 (en) 2018-06-29 2019-07-01 Compositions and methods of using itaconic acid derivatives

Country Status (5)

Country Link
US (1) US12060310B2 (cg-RX-API-DMAC7.html)
EP (1) EP3813815B1 (cg-RX-API-DMAC7.html)
JP (1) JP7396682B2 (cg-RX-API-DMAC7.html)
ES (1) ES3063485T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020006557A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL287444B2 (en) 2019-04-30 2024-09-01 Sitryx Therapeutics Ltd Itaconic acid derivatives and uses thereof in treating an inflammatory disease or a disease associated with an undesirable immune response
FI4081511T6 (fi) 2019-12-23 2026-06-09 Sitryx Therapeutics Ltd Karboksijohdannaisia, joilla on anti-inflammatorisia ominaisuuksia
EP4237404A1 (en) * 2020-10-29 2023-09-06 Sitryx Therapeutics Limited Novel compounds
EP4326247A1 (en) 2021-04-23 2024-02-28 Helmholtz-Zentrum für Infektionsforschung GmbH Citraconic acid and derivatives thereof for use as a medicament
CN119685257B (zh) * 2024-12-16 2026-02-27 华中科技大学同济医学院附属协和医院 体外诱导t细胞免疫记忆分化的方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260479A (en) * 1991-12-16 1993-11-09 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
DK1062954T3 (da) * 1998-10-27 2007-09-10 Suntory Ltd Anvendelse af itakonsyre til regulering af det glykotiske stofskifte
US8293925B2 (en) * 2009-09-21 2012-10-23 Chemocentryx, Inc. Pyrrolidinone carboxamide derivatives
LU91877B1 (en) 2011-09-23 2013-03-25 Univ Luxembourg Method to predict the presence of itaconic Acid, IRG1 and/or protein IRG1 in a subject and pharmaceutical composition for performing gene therapy
US8691993B2 (en) * 2011-12-12 2014-04-08 Hoffmann-La Roche Inc. Piperidinyl naphthylacetic acids
WO2013150534A1 (en) * 2012-04-03 2013-10-10 Aposense Ltd. Novel targeting agents for diagnostic and therapeutic indications
EP3416634A4 (en) * 2016-02-15 2019-10-09 Artyomov, Maxim IMMUNOMODULATORY AGENTS AND METHOD FOR USE THEREOF

Also Published As

Publication number Publication date
EP3813815A1 (en) 2021-05-05
EP3813815C0 (en) 2026-01-28
US12060310B2 (en) 2024-08-13
EP3813815A4 (en) 2022-04-20
EP3813815B1 (en) 2026-01-28
US20210261495A1 (en) 2021-08-26
JP2021529752A (ja) 2021-11-04
JP7396682B2 (ja) 2023-12-12
WO2020006557A1 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CO2017011484A2 (es) Inhibidores de bromodominio
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
CL2018001230A1 (es) Tratamiento de osteoartritis
AR120223A1 (es) Proteínas que unen nkg2d, cd16 y flt3
CL2020001797A1 (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas.
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
MX2019009848A (es) Proteínas que se unen a her2, nkg2d y cd16.
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
MX2017015838A (es) Composiciones y metodos para tratar pterigion.
MX2018016287A (es) Derivados de pirazolopirimidina como inhibidor de cinasa.
CL2016000783A1 (es) “compuestos derivados de isoquinolinona y quinazolinona, inhibidores pi3k; composición farmacéutica que los comprende; útiles en el tratamiento del cáncer, enfermedades inflamatorias y autoinmune”. pct
CR20190394A (es) Compuestos de inhibidores de autotaxina
BR112016023558A2 (pt) compostos úteis como imunomoduladores
MX2016011038A (es) Compuestos para el tratamiento de trastornos mediados por complemento.
CO2018011105A2 (es) 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj)
CO2018007221A2 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
MX2018014114A (es) Derivados del sobetiroma.
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
CL2017000317A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d
CL2017001615A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2.